- Home
- NAUT vs UNCY Comparison
NAUT vs UNCY Comparison
Compare NAUT & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAUT | UNCY |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.4M | 121.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAUT | UNCY |
|---|---|---|
| Price | $1.86 | $6.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 345.8K | ★ 384.0K |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $3.71 |
| 52 Week High | $2.54 | $11.00 |
Technical Indicators
Market Signals| Indicator | NAUT | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 57.10 |
| Support Level | $1.96 | $6.31 |
| Resistance Level | $2.13 | $6.95 |
| Average True Range (ATR) | 0.18 | 0.42 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 5.86 | 53.72 |
Price Performance
Historical ComparisonAbout NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.